{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-275300","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.477761+00:00","generated_at":"2026-06-08T05:05:55.660286+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Nurix presents updated clinical guidance, NX-2127 Phase 1 details","bullets":["Investor presentation includes updated guidance on clinical programs.","Additional detail on Phase 1 trial of NX-2127 for B-cell malignancies provided.","Meetings with analysts and investors begin November 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-275300","json":"https://secwatch.observer/filing/0001193125-23-275300.json","markdown":"https://secwatch.observer/filing/0001193125-23-275300.md","text":"https://secwatch.observer/filing/0001193125-23-275300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312523275300/0001193125-23-275300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312523275300/d541490d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:05:55.660286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}